Skip to content

AnaptysBio, Inc. ANAB Short- and long-term operating lease liabilities

Short- and long-term operating lease liabilities at other companies

Roivant Sciences logo
Roivant SciencesROIV

Other financials

Income statement

See full
Revenue$25.6M-8.0%
Operating income-$34.6M-25.8%
Net income-$52.9M-34.5%
EPS (diluted)-$1.84-43.8%

Balance sheet

See full
Cash & equivalents$248.5M+152%
Total debt$13.6K-99.9%
Total equity$12.7M-62.5%
Total assets$329.7M-21.9%

Cash flow

See full
Operating cash flow-$25.9M-142%
CapEx$17.0K-51.4%
Free cash flow-$25.9M-142%

Valuation

See full
Market cap$1.73B+180%
Enterprise value$1.48B+176%
P/S7.4×+1.9×

Profitability

See full
Operating margin17.6%+9.6pp
Net margin-49.9%-22.6pp
FCF margin1.9%+1.0pp

Returns & leverage

See full
Return on equity-343.8%-1,012pp
Debt / equity-0.5×
Current ratio7.6×-0.7×

Where this comes from

Reported directly by AnaptysBio, Inc. in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOperatingLeaseLiability.

The official record: AnaptysBio, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about AnaptysBio, Inc.'s short- and long-term operating lease liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is AnaptysBio, Inc.'s short- and long-term operating lease liabilities?
AnaptysBio, Inc. (ANAB) reported short- and long-term operating lease liabilities of -$499K in Q1 2026.
How has AnaptysBio, Inc.'s short- and long-term operating lease liabilities changed year-over-year?
AnaptysBio, Inc.'s short- and long-term operating lease liabilities decreased by 8.0% year-over-year, from -$462K to -$499K.
What is the long-term trend for AnaptysBio, Inc.'s short- and long-term operating lease liabilities?
Over 3 years (2022 to 2025), AnaptysBio, Inc.'s short- and long-term operating lease liabilities has grown at a 8.6% compound annual growth rate (CAGR), from -$1.51M to -$1.93M.